Expert InterviewLLY
Slingshot members are talking to an expert! The topic is:
Discussing the topline data from Lilly's SURMOUNT-OSA Phase 3 trial on tirzepatide for patients with Obstructive Sleep Apnea and the impact on the use of CPAP
Executed on:Jul 3, 2024 2:00 PM EDT
Call Duration:30 minutes
Expert Profile
ExpertBlinded Expert
Institution: Johns Hopkins
- Medical Director, Johns Hopkins Sleep Disorders Center and Associate Professor of Neurology at JHU School of Medicine.
- Actively treats over 1,500 patients with OSA, 20-30 patients with Narcolepsy, and 40-50 patients with Idiopathic Hypersomnia.
- Research interests are in the area of sleep medicine, specifically investigating the co-morbid health consequences of chronic sleep deprivation.
Interview Goal
Looking at the recent New England Journal of Medicine results of Tirzepatide and its impact on sleep apnea. This call will discuss the topline results of the SURMOUNT-OSA phase 3 clinical trials that showed tirzepatide injection (10 mg or 15 mg) significantly reduced the apnea-hypopnea index (AHI) compared to placebo, achieving the primary endpoints.